Abstract
Treatment advances in psychotic disorders are limited by the use of phenomenological diagnoses identified by symptomatic outcomes, rather than by neurobiological constructs defined by quantitative characteristics. The Bipolar-Schizophrenia Network for Intermediate Phenotypes (BSNIP) has proposed neurobiologically-derived psychosis “Biotypes”, each with distinct biomarker profiles including diametrically opposed deviations in intrinsic neural activity. Neurophysiological models of psychosis suggest that intrinsic activity (IA) deviations may be a biologically-mediated core deficit in psychosis. Here we investigate differential effects of various medications on IA and whether these effects differ between Biotypes.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
